News

Location Change for Servatus

1 April 2017

Servatus Ltd Moves offices to the University of the Sunshine Coast

April 2017 saw Servatus Ltd relocating to the University of the Sunshine Coast, with laboratories set up on the university campus and offices just minutes away in the renowned Innovation Centre. Located in one of the country's fastest growing regions, the University of the Sunshine Coast campus at Sippy Downs has grown to accommodate more than 10,000 students since opening in 1996.

“We have found USC very progressive in its thinking and very willing to accommodate industry linkages that will benefit both.” said Managing Director Dr Wayne Finlayson. Servatus look forward to developing and strengthening the relationship with the University and its students furthermore over time.

For Servatus, the construction of the Sunshine Coast University Hospital and the establishment of the clinical trials department at the University paves a pathway for ground-breaking opportunities in research directed at selectively improving specific characteristics of existing therapeutic proteins to enhance their clinical utility.

The Sunshine Coast area is expanding rapidly and offers a balance of lifestyle and innovation, as well as reduced costs of living in contrast to major cities. Located only an hour away from the State’s capital city of Brisbane, the Sunshine Coast has been affectionately known as the Silicon Valley of Australia. Servatus aims to launch projects in the near future, providing the university with employment opportunities for local graduates.

Read more

New Director Appointed

1 February 2017

February 2017 New Director Appointed Michael Vitale joins the board of Servatus Ltd

In February 2017, Servatus expanded the board by appointing Michael Vitale as Non-Executive Director. From an extensive career in both the USA and Australia, Michael brings a lifetime of experience in the commercialisation of science to the company. Michael has a wealth of knowledge in commercialisation, research and teaching.

Michael has previously acted as a non-executive director in both listed and unlisted companies. His experience in the commercialisation of science and life sciences in particular makes Michael an invaluable addition to Servatus. Michael holds citizenships in both Australia and the US.

Together with our Executive Director Wayne Finlayson and Director Wolf Hanisch, Michael further enables the progression of Servatus and the proceeding of pre-clinical work before moving to clinical trials.

Michael holds tertiary qualifications in mathematics from Oakland University in Michigan and Darttmouth College in New Hampshire (PhD, Mathematics), as well as an MBA from Havard Business School in the USA. Throughout his career, Michael has held the position of Professor at a range of leading universities across Australia and the US.

Michael has been the adjunct professor for over two years at the University of Melbourne, where he teaches entrepreneurship to MBA students at the Melbourne Business School and to graduate students in the School of Engineering and the School of Information. He also co-teaches bio-design innovation in a unit jointly set up by the Melbourne Business School and the Melbourne School of Engineering.

Previously he was both professor and director at Monash University with positions at the Monash Asia-Pacific Centre for Science and Wealth Creation (2006 to 2012) and (2008 to 2015) the Faculty of Information Technology. Both of these roles involved a range of responsibilities across research, teaching, commercial and management functions.

Over his career, Michael has contributed to several books and written a large number of professional publications, journal articles, conference papers and case studies.

Michael chaired ASX-listed Medical Therapies Ltd, now Cellmid from 2005 to 2008. The company was involved in the commercialisation of anti-inflammatory and anti-cancer therapeutics and entered clinical trials with its first product in Feb 2008.

The addition of Michael expands the knowledge base and experience of Servatus immensely. Michael shares our vision of commercialising our proprietary technology working in due course with one or more corporate partners in the bio-pharmaceutical industry.

Read more

Servatus Pty Ltd Changes Status to Public Unlisted Company

1 December 2016

Servatus Pty Ltd changes status to Public unlisted company and is now Servatus Ltd

In December 2016, Servatus Pty Ltd changed its status from propriety limited to an unlisted public company, becoming Servatus Ltd. As our number of shareholders grow, we see this status change as a step forward in the company’s progress.

This change of status from propriety limited to unlisted public creates a higher level of transparency and aims to provide greater protection of the public. With this new status comes a number of certain requirements that must be met. An unlisted public company registered under the Corporations Act must have at least three directors, two of whom must be Australian residents. Servatus Ltd recently met this requirement with the addition of Michael Vitale, our newly appointed Non-Executive Director. Michael expands Servatus, bringing a comprehensive mix of commercial, research and teaching experience from a wide-ranging career in both the USA and Australia.

Servatus was established in 2012, initially beginning operations in 2013. Our early necessary operations for filing of our patent pending to protect our core technology was financed by a preliminary capital investment. Today, Servatus still holds a clear vision to commercialise our proprietary technology, working in due course with our core technology.

As Servatus continues to progress, the number of shareholders permitted for a propriety limited company approached its limits. This growth in shareholders and the objective to create more transparency within the company gives reason enough for the status change from propriety unlimited to unlisted public. Servatus continues to target development of biological treatments and drugs for chronic inflammatory and auto-immune diseases that work by new modes.

Read more